Video

Dr. Popat on the Investigation of Lurbinectedin in Second-line SCLC

Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.

Sanjay Popat, MBBS, FRCP, PhD, medical oncologist, the Royal Marsden NHS Foundation Trust, professor of Thoracic Oncology, the Institute of Cancer Research, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer (SCLC). 

A phase 2 basket trial (NCT02454972) evaluated the safety and efficacy of lurbinectedin in patients with solid tumors, including SCLC. Data from the SCLC cohort showed that lurbinectedin elicited an overall response rate (ORR) of 35.2% per investigator assessment, Popat says. Notably, patients with chemotherapy-resistant disease experienced an ORR of 22.2% with lurbinectedin, which was higher than the 5% that was expected in that setting, Popat adds. The median progression-free survival benefit observed with the agent was also meaningful, according to Popat.

Since this was a single-arm study, it is difficult to make comparisons with it— especially since there may have been an element of patient selection bias as is inevitable in trials of relapsed SCLC, Popat adds.Regardless, these data were the first signal that lurbinectedin may be a beneficial option in this patient population, Popat concludes. 

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center